Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Information date: 4 September 2026 — On 13 January 2026, FDA said its review did not find an increased risk of suicidal ideation or behaviour with GLP-1 receptor agonists and requested removal of that warning from affect
Information date: 4 September 2026 — FDA reported on 31 August 2026 an international collaboration intended to advance testing methods that reduce reliance on horseshoe-crab blood, an important source used in traditional
Information date: 4 September 2026 — ICH Q11, adopted by FDA, describes science- and risk-based development and manufacture of drug substances, including the relationship among starting materials, process understanding,
Information date: 4 September 2026 — ClinicalTrials.gov structures a study record into identification, status, sponsor, oversight, design, arms, outcomes, eligibility, contacts and result modules, allowing readers to com
Information date: 4 September 2026 — FDA and the Center for Research on Complex Generics scheduled a free two-day workshop for 23–24 September 2026 on development and assessment of generic GLP-1 products. Knowing that st
Information date: 4 September 2026 — FDA defines a combination product as a product composed of two or more regulated components, including drug-device combinations, and assigns oversight according to the product’s prima
Information date: 3 September 2026 — EMA reported that its human medicines committee adopted a positive opinion in May 2026 on adding an oral tablet formulation of Wegovy. For accurate reporting, that committee recommend
Information date: 3 September 2026 — FDA published seventeen revised draft product-specific guidances for generic peptide products on 28 July 2026. The useful signal for development teams is not merely the number of docu
Information date: 3 September 2026 — Peptide skincare marketing often compresses cell studies, animal models, formulation tests and human outcomes into one claim. A small randomized study of a topical GHK-Cu regimen afte
